Cyxone AB (publ)
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CYXO.ST research report →
Companywww.cyxone.com
Cyxone AB (publ), a clinical biotech company, develops disease modifying therapies for rheumatoid arthritis, multiple sclerosis, and treatments for virally induced acute respiratory disorders. Its development portfolio comprises Rabeximod in a clinical Phase II program for rheumatoid arthritis and Covid-19 infections; and T20K, a Phase 1 candidate drug for the treatment of multiple sclerosis. The company was incorporated in 2015 and is based in Malmö, Sweden.
- CEO
- Kjell G. Stenberg
- IPO
- 2016
- Employees
- 3
- HQ
- Malmö, SE
Price Chart
Valuation
- Market Cap
- $6.75M
- P/E
- -0.08
- P/S
- 1.31
- P/B
- 0.05
- EV/EBITDA
- 0.49
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 50.72%
- Op Margin
- -420.77%
- Net Margin
- -446.56%
- ROE
- -53.52%
- ROIC
- -54.40%
Growth & Income
- Revenue
- $5.15M · -19.55%
- Net Income
- $-22,989,000 · 45.87%
- EPS
- $-0.22 · 50.00%
- Op Income
- $-21,661,000
- FCF YoY
- 47.51%
Performance & Tape
- 52W High
- $0.16
- 52W Low
- $0.01
- 50D MA
- $0.02
- 200D MA
- $0.06
- Beta
- 0.42
- Avg Volume
- 1.73M
Get TickerSpark's AI analysis on CYXO.ST
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our CYXO.ST Coverage
We haven't published any research on CYXO.ST yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate CYXO.ST Report →